Medical Meetings

Lasofoxifene Reduced ESR1 Mutant Allele Fraction and Provided Clinical Benefit versus Fulvestrant in Metastatic Breast Cancer: the ELAINE 1 trial

DOWNLOAD

Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors

DOWNLOAD

Durable Complete Remission of Metastatic ER+/HER2− Breast Cancer after Lasofoxifene Therapy

DOWNLOAD

Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined with Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

DOWNLOAD

Lasofoxifene as a Potential Treatment for Aromatase Inhibitor Resistant ER+ Breast Cancer

DOWNLOAD

Lasofoxifene alone or in combination with palbociclib is an effective treatment for therapy-resistant ER-positive metastatic breast cancer

DOWNLOAD

Patient Knowledge, Attitudes and Perceptions Regarding Breast Cancer Biomarkers, Testing, and Quality of Life

DOWNLOAD

A Preliminary Assessment of Knowledge, Attitudes, and Awareness Surrounding Precision Medicine, ESR1 Mutations, and Biomarker Testing Amongst Medical Oncologists

DOWNLOAD

Lasofoxifene alone or in combination with palbociclib is an effective treatment for therapy-resistant ER-positive metastatic breast cancer

DOWNLOAD

An Open-label, Randomized, Multi-center Phase 2 Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

DOWNLOAD

Lasofoxifene Decreases Breast Cancer Lung and Liver Metastasis in a Mammary Intraductal (MIND) Xenograft Model of Mutant ERa+ Breast Cancer

DOWNLOAD

Physician Perceptions of Estrogen Agonist/Antagonists in Menopausal Health: A Survey to Address Osteoporosis, Urogenital Health and Breast Concerns in Menopause and Breast Cancer Survivorship

DOWNLOAD

A Preliminary Assessment of Knowledge, Attitudes, and Awareness Surrounding Precision Medicine, ESR1 Mutations, and Biomarker Testing Amongst Medical Oncologists

DOWNLOAD

Lasofoxifene 0.25 mg Compared with Raloxifene 60 mg for Effects on Bone Mineral Density and Markers of Bone Turnover: Results from the Phase 3 Comparison of Raloxifene and Lasofoxifene (CORAL) Trial

DOWNLOAD

Reported Sexual Activity and Orgasm Frequency in a Comparative Study of the SERMs Lasofoxifene and Raloxifene in an Osteoporosis Prevention Study

DOWNLOAD

Lasofoxifene, an Estrogen Agonist/Antagonist, Improves Symptoms of Genitourinary Syndrome and Menopause (GSM) and Physiologic Markers Associated with Vulvovaginal Atrophy (VVA) in Two Large Phase 3 Studies

DOWNLOAD